Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selenium and Melatonin for Ocular Ischemic Syndrome
NCT04005222Phase 1Completed
- Sponsor
- Beytepe Murat Erdi Eker State Hospital
- Start
- May 2014
- Primary completion
- Sep 2016
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, open-label trial of selenium and melatonin in ocular ischemic syndrome (OIS), sponsored by Beytepe Murat Erdi Eker State Hospital. Primary endpoint: Malondialdehyde at 4 weeks. Started May 2014; status: completed.
02
Drugs
seleniummelatonin
03
Conditions
ocular ischemic syndrome (OIS)
Beyond the preview
Go deeper on NCT04005222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04005222.